News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AbbVie (ABBV)’s New, Cheaper Hepatitis C Drug Could Launch The Drug World’s Own Hunger Games



8/7/2017 8:03:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
AbbVie Inc.’s newly approved drug Mavyret can treat hepatitis C’s six major strains in eight weeks.

It’s also a positive steal in the hepatitis C drug world, at $26,400 for a eight-week course of treatment.

That’s on paper, at least, according to a chart from EvercoreISI analyst Umer Raffat, which shows AbbVie’s Mavyret coming in cheaper than the company’s other hepatitis C therapies, Viekira Pak and Viekira XR, Gilead Sciences Inc.’s Sovaldi, Harvoni, Epclusa and Vosevi, and Merck’s Zepatier.

Read at Market Watch


comments powered by Disqus
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES